 Rebecca Wolsky
Concepts (130)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 4 | 2023 | 141 | 1.620 |
Why?
| | Ovarian Neoplasms | 4 | 2022 | 388 | 1.280 |
Why?
| | Struma Ovarii | 2 | 2022 | 7 | 1.010 |
Why?
| | Tertiary Care Centers | 1 | 2023 | 126 | 0.830 |
Why?
| | Thyroid Neoplasms | 2 | 2022 | 264 | 0.800 |
Why?
| | Immunohistochemistry | 3 | 2023 | 1629 | 0.790 |
Why?
| | Carcinoma, Endometrioid | 2 | 2022 | 46 | 0.740 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2023 | 439 | 0.710 |
Why?
| | Uterine Cervical Neoplasms | 2 | 2020 | 216 | 0.650 |
Why?
| | Squamous Intraepithelial Lesions of the Cervix | 1 | 2018 | 3 | 0.620 |
Why?
| | Fallopian Tube Neoplasms | 1 | 2018 | 14 | 0.610 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2018 | 57 | 0.610 |
Why?
| | Ki-67 Antigen | 1 | 2018 | 103 | 0.600 |
Why?
| | SOXB1 Transcription Factors | 1 | 2018 | 60 | 0.600 |
Why?
| | Hyperplasia | 1 | 2018 | 163 | 0.580 |
Why?
| | Biomarkers, Tumor | 3 | 2023 | 1040 | 0.570 |
Why?
| | Adenocarcinoma, Clear Cell | 1 | 2017 | 14 | 0.570 |
Why?
| | Mutation | 4 | 2023 | 3345 | 0.570 |
Why?
| | Carcinosarcoma | 1 | 2017 | 17 | 0.570 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2017 | 25 | 0.570 |
Why?
| | Sentinel Lymph Node | 1 | 2017 | 37 | 0.550 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2017 | 99 | 0.540 |
Why?
| | Earache | 1 | 2015 | 4 | 0.500 |
Why?
| | Actinomycosis | 1 | 2015 | 3 | 0.500 |
Why?
| | Actinomyces | 1 | 2015 | 4 | 0.500 |
Why?
| | Maxillary Sinusitis | 1 | 2015 | 7 | 0.500 |
Why?
| | beta Catenin | 4 | 2023 | 219 | 0.490 |
Why?
| | Wnt Proteins | 2 | 2021 | 134 | 0.270 |
Why?
| | Neoplasm Grading | 3 | 2022 | 242 | 0.230 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2023 | 31 | 0.220 |
Why?
| | DNA Polymerase II | 1 | 2023 | 37 | 0.220 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2023 | 17 | 0.220 |
Why?
| | DNA Mismatch Repair | 1 | 2023 | 37 | 0.220 |
Why?
| | Female | 13 | 2023 | 59488 | 0.210 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2023 | 445 | 0.210 |
Why?
| | Iodine Radioisotopes | 1 | 2022 | 125 | 0.200 |
Why?
| | Wnt Signaling Pathway | 2 | 2021 | 146 | 0.190 |
Why?
| | Cervix Uteri | 1 | 2020 | 45 | 0.180 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2020 | 38 | 0.180 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 332 | 0.160 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2019 | 52 | 0.160 |
Why?
| | Granular Cell Tumor | 1 | 2018 | 7 | 0.160 |
Why?
| | Humans | 16 | 2023 | 114654 | 0.160 |
Why?
| | Cell Proliferation | 2 | 2018 | 2186 | 0.160 |
Why?
| | Phyllodes Tumor | 1 | 2018 | 2 | 0.160 |
Why?
| | Neoadjuvant Therapy | 1 | 2020 | 304 | 0.150 |
Why?
| | Prognosis | 2 | 2023 | 3327 | 0.150 |
Why?
| | Cystadenoma, Serous | 1 | 2018 | 18 | 0.150 |
Why?
| | Fallopian Tubes | 1 | 2018 | 29 | 0.150 |
Why?
| | Tumor Microenvironment | 1 | 2020 | 430 | 0.150 |
Why?
| | Organotechnetium Compounds | 1 | 2017 | 10 | 0.140 |
Why?
| | Indocyanine Green | 1 | 2017 | 12 | 0.140 |
Why?
| | Mucous Membrane | 1 | 2018 | 108 | 0.140 |
Why?
| | Colorimetry | 1 | 2017 | 14 | 0.140 |
Why?
| | Single Photon Emission Computed Tomography Computed Tomography | 1 | 2017 | 10 | 0.140 |
Why?
| | Surgical Oncology | 1 | 2017 | 18 | 0.140 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2017 | 47 | 0.140 |
Why?
| | Epithelium | 1 | 2018 | 295 | 0.140 |
Why?
| | Coloring Agents | 1 | 2017 | 72 | 0.140 |
Why?
| | Ovary | 1 | 2018 | 191 | 0.140 |
Why?
| | Lymph Node Excision | 1 | 2017 | 139 | 0.130 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2018 | 308 | 0.130 |
Why?
| | Maxillary Sinus | 1 | 2015 | 11 | 0.130 |
Why?
| | Gynecology | 1 | 2017 | 163 | 0.120 |
Why?
| | Middle Aged | 5 | 2023 | 26732 | 0.120 |
Why?
| | Adenocarcinoma | 1 | 2020 | 795 | 0.110 |
Why?
| | Neoplasm Staging | 1 | 2017 | 1167 | 0.110 |
Why?
| | Societies, Medical | 1 | 2017 | 663 | 0.110 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2021 | 1141 | 0.110 |
Why?
| | HMGA2 Protein | 1 | 2013 | 8 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1355 | 0.100 |
Why?
| | Aged, 80 and over | 1 | 2023 | 6345 | 0.100 |
Why?
| | Epithelial Cells | 1 | 2018 | 950 | 0.100 |
Why?
| | Prospective Studies | 1 | 2023 | 6217 | 0.100 |
Why?
| | Estrogen Receptor alpha | 1 | 2013 | 121 | 0.100 |
Why?
| | Skin Neoplasms | 1 | 2018 | 756 | 0.090 |
Why?
| | Prostatic Neoplasms | 1 | 2018 | 921 | 0.090 |
Why?
| | Receptors, Progesterone | 1 | 2013 | 319 | 0.090 |
Why?
| | Receptor, ErbB-2 | 1 | 2013 | 300 | 0.090 |
Why?
| | Inflammation | 1 | 2020 | 2478 | 0.090 |
Why?
| | Paired Box Transcription Factors | 1 | 2010 | 36 | 0.090 |
Why?
| | SOXE Transcription Factors | 1 | 2010 | 17 | 0.090 |
Why?
| | Aged | 3 | 2023 | 19068 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2010 | 67 | 0.080 |
Why?
| | Proto-Oncogene Proteins | 1 | 2013 | 608 | 0.080 |
Why?
| | Adult | 3 | 2023 | 30542 | 0.070 |
Why?
| | Cell Line, Tumor | 3 | 2021 | 2710 | 0.060 |
Why?
| | Melanoma | 1 | 2010 | 620 | 0.050 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2023 | 309 | 0.050 |
Why?
| | RNA | 2 | 2023 | 809 | 0.050 |
Why?
| | Breast Neoplasms | 1 | 2013 | 1862 | 0.050 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2021 | 28 | 0.050 |
Why?
| | Indazoles | 1 | 2021 | 58 | 0.050 |
Why?
| | Hospitals, General | 1 | 2020 | 19 | 0.050 |
Why?
| | Papanicolaou Test | 1 | 2020 | 39 | 0.040 |
Why?
| | Vaginal Smears | 1 | 2020 | 50 | 0.040 |
Why?
| | Imidazoles | 1 | 2021 | 208 | 0.040 |
Why?
| | Chromatin | 1 | 2023 | 428 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 316 | 0.040 |
Why?
| | Dynactin Complex | 1 | 2018 | 4 | 0.040 |
Why?
| | Sequestosome-1 Protein | 1 | 2018 | 13 | 0.040 |
Why?
| | Oncogene Fusion | 1 | 2018 | 9 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2021 | 347 | 0.040 |
Why?
| | Metaplasia | 1 | 2018 | 54 | 0.040 |
Why?
| | Kallikreins | 1 | 2018 | 30 | 0.040 |
Why?
| | Recurrence | 1 | 2021 | 935 | 0.040 |
Why?
| | GATA3 Transcription Factor | 1 | 2018 | 24 | 0.040 |
Why?
| | Cell Survival | 1 | 2021 | 1020 | 0.040 |
Why?
| | Pyridines | 1 | 2021 | 425 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1121 | 0.040 |
Why?
| | Prostate-Specific Antigen | 1 | 2018 | 151 | 0.040 |
Why?
| | Disease Management | 1 | 2021 | 560 | 0.040 |
Why?
| | Survival Rate | 1 | 2020 | 1644 | 0.030 |
Why?
| | Biopsy | 1 | 2018 | 1036 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2020 | 4411 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2013 | 523 | 0.020 |
Why?
| | PAX3 Transcription Factor | 1 | 2010 | 11 | 0.020 |
Why?
| | Up-Regulation | 1 | 2013 | 807 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 1947 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2010 | 535 | 0.020 |
Why?
| | Child, Preschool | 1 | 2018 | 9111 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2020 | 12544 | 0.010 |
Why?
| | Young Adult | 1 | 2018 | 10465 | 0.010 |
Why?
| | Disease Progression | 1 | 2010 | 2380 | 0.010 |
Why?
| | Male | 2 | 2018 | 55579 | 0.010 |
Why?
| | Apoptosis | 1 | 2010 | 2362 | 0.010 |
Why?
| | Adolescent | 1 | 2018 | 17837 | 0.010 |
Why?
| | Child | 1 | 2018 | 18407 | 0.010 |
Why?
| | Mice | 1 | 2013 | 14863 | 0.010 |
Why?
| | Animals | 1 | 2013 | 31698 | 0.010 |
Why?
|
|
Wolsky's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|